Bispecific immune cell engagers (BiIE), such as T cell engagers and NK cell engagers, are special forms of tandem scFv. In which, one scFv binds to immune cells via the specific marker, such as CD3 of T cells, and the other scFv binds tumors via the tumor-associated antigen (TAA). This type of the molecules retarget immune cells to tumor cells and have shown great potentials in the studies of cancer therapy.
Scientists from Creative Biolabs have successfully constructed and engineered several bispecific immune cell engagers. Theoretically, bispecific immune cell engagers against any tumor marker can be constructed. Besides expression and purification of bispecific molecules, we can also provide ELISA/FACS binding assays, cell cytotoxic and apoptosis assays, etc.
Cat. No. | Product Name | scFv1 | scFv2 |
CBL-BiIE001-01 | CEA-CD3 BiIE | OKT3 (Original) | Anti-CEA scFv |
CBL-BiIE001-11 | CEA-CD3 BiIE | OKT3 (Revised) | Anti-CEA scFv |
CBL-BiIE002-01 | EPCAM-CD3 BiIE | OKT3 (Original) | Anti-EPCAM scFv |
CBL-BiIE002-11 | EPCAM-CD3 BiIE | OKT3 (Revised) | Anti-EPCAM scFv |
CBL-BiIE003-01 | EGFR-CD3 BiIE | OKT3 (Original) | Cetuximab scFv |
CBL-BiIE003-11 | EGFR-CD3 BiIE | OKT3 (Revised) | Cetuximab scFv |
CBL-BiIE003-02 | EGFR-CD3 BiIE | OKT3 (Original) | Panitumumab scFv |
CBL-BiIE003-12 | EGFR-CD3 BiIE | OKT3 (Revised) | Panitumumab scFv |
CBL-BiIE005-01 | CD19-CD3 BiIE | OKT3 (Original) | Anti-CD19 scFv |
CBL-BiIE005-11 | CD19-CD3 BiIE | OKT3 (Revised) | Anti-CD19 scFv |
CBL-BiIE008-01 | HER2-CD3 BiIE | OKT3 (Original) | Trastuzumab scFv |
CBL-BiIE008-11 | HER2-CD3 BiIE | OKT3 (Revised) | Trastuzumab scFv |
CBL-BiIE008-02 | HER2-CD3 BiIE | OKT3 (Original) | Pertuzumab scFv |
CBL-BiIE008-12 | HER2-CD3 BiIE | OKT3 (Revised) | Pertuzumab scFv |
CBL-BiIE009-01 | sTn-CD3 BiIE | OKT3 (Original) | Anti-sTn scFv |
CBL-BiIE009-11 | sTn-CD3 BiIE | OKT3 (Revised) | Anti-sTn scFv |
CBL-BiIE009-12 | CD20-CD3 BiIE | OKT3 (Original) | Anti-CD20 scFv |
CBL-BiIE009-13 | CD20-CD3 BiIE | OKT3 (Revised) | Anti-CD20 scFv |
CBL-BiIE009-16 | CD33-CD3 BiIE | OKT3 (Original) | Anti-CD33 scFv |
CBL-BiIE009-17 | CD33-CD3 BiIE | OKT3 (Revised) | Anti-CD33 scFv |
CBL-BiIE009-18 | CD133-CD3 BiIE | OKT3 (Original) | Anti-CD133 scFv |
CBL-BiIE009-19 | CD133-CD3 BiIE | OKT3 (Revised) | Anti-CD133 scFv |
CBL-BiIE009-20 | PSMA-CD3 BiIE | OKT3 (Original) | Anti-PSMA scFv |
CBL-BiIE009-21 | PSMA-CD3 BiIE | OKT3 (Revised) | Anti-PSMA scFv |
CBL-BiIE009-22 | CD30-CD3 BiIE | OKT3 (Original) | Anti-CD30 scFv |
CBL-BiIE009-23 | CD30-CD3 BiIE | OKT3 (Revised) | Anti-CD30 scFv |
CBL-BiIE009-24 | CD47-CD3 BiIE | OKT3 (Original) | Anti-CD47 scFv |
CBL-BiIE009-25 | CD47-CD3 BiIE | OKT3 (Revised) | Anti-CD47 scFv |
CBL-BiIE009-26 | CD52-CD3 BiIE | OKT3 (Original) | Anti-CD52 scFv |
CBL-BiIE009-27 | CD52-CD3 BiIE | OKT3 (Revised) | Anti-CD52 scFv |
CBL-BiIE009-28 | gpA33-CD3 BiIE | OKT3 (Original) | Anti-gpA33 scFv |
CBL-BiIE009-29 | gpA33-CD3 BiIE | OKT3 (Revised) | Anti-gpA33 scFv |
CBL-BiIE009-30 | TAG-72-CD3 BiIE | OKT3 (Original) | Anti-TAG-72 scFv |
CBL-BiIE009-31 | TAG-72-CD3 BiIE | OKT3 (Revised) | Anti-TAG-72 scFv |
CBL-BiIE009-32 | Mucin-CD3 BiIE | OKT3 (Original) | Anti-Mucin scFv |
CBL-BiIE009-33 | Mucin-CD3 BiIE | OKT3 (Revised) | Anti-Mucin scFv |
CBL-BiIE009-34 | CIX-CD3 BiIE | OKT3 (Original) | Anti-CIX scFv |
CBL-BiIE009-35 | CIX-CD3 BiIE | OKT3 (Revised) | Anti-CIX scFv |
CBL-BiIE009-36 | PSMA-CD3 BiIE | OKT3 (Original) | Anti-PSMA scFv |
CBL-BiIE009-37 | PSMA-CD3 BiIE | OKT3 (Revised) | Anti-PSMA scFv |
CBL-BiIE009-38 | GD2-CD3 BiIE | OKT3 (Original) | Anti-GD2 scFv |
CBL-BiIE009-39 | GD2-CD3 BiIE | OKT3 (Revised) | Anti-GD2 scFv |
CBL-BiIE009-40 | GD3-CD3 BiIE | OKT3 (Original) | Anti-GD3 scFv |
CBL-BiIE009-41 | GD3-CD3 BiIE | OKT3 (Revised) | Anti-GD3 scFv |
CBL-BiIE009-42 | GM2-CD3 BiIE | OKT3 (Original) | Anti-GM2 scFv |
CBL-BiIE009-43 | GM2-CD3 BiIE | OKT3 (Revised) | Anti-GM2 scFv |
CBL-BiIE009-44 | VEGFR-CD3 BiIE | OKT3 (Original) | Anti-VEGFR scFv |
CBL-BiIE009-45 | VEGFR-CD3 BiIE | OKT3 (Revised) | Anti-VEGFR scFv |
CBL-BiIE009-46 | Integrin-CD3 BiIE | OKT3 (Original) | Anti-Integrin scFv |
CBL-BiIE009-47 | Integrin-CD3 BiIE | OKT3 (Revised) | Anti-Integrin scFv |
CBL-BiIE009-48 | MET-CD3 BiIE | OKT3 (Original) | Anti-MET scFv |
CBL-BiIE009-49 | MET-CD3 BiIE | OKT3 (Revised) | Anti-MET scFv |
CBL-BiIE009-50 | IGF1R-CD3 BiIE | OKT3 (Original) | Anti-IGF1R scFv |
CBL-BiIE009-51 | IGF1R-CD3 BiIE | OKT3 (Revised) | Anti-IGF1R scFv |
CBL-BiIE009-52 | EPHA3-CD3 BiIE | OKT3 (Original) | Anti-EPHA3 scFv |
CBL-BiIE009-53 | EPHA3-CD3 BiIE | OKT3 (Revised) | Anti-EPHA3 scFv |
CBL-BiIE009-54 | TRAILR1-CD3 BiIE | OKT3 (Original) | Anti-TRAILR1 scFv |
CBL-BiIE009-55 | TRAILR1-CD3 BiIE | OKT3 (Revised) | Anti-TRAILR1 scFv |
CBL-BiIE009-56 | TRAILR2-CD3 BiIE | OKT3 (Original) | Anti-TRAILR2 scFv |
CBL-BiIE009-57 | TRAILR2-CD3 BiIE | OKT3 (Revised) | Anti-TRAILR2 scFv |
CBL-BiIE009-58 | RANKL-CD3 BiIE | OKT3 (Original) | Anti-RANKL scFv |
CBL-BiIE009-59 | RANKL-CD3 BiIE | OKT3 (Revised) | Anti-RANKL scFv |
CBL-BiIE009-60 | FAP-CD3 BiIE | OKT3 (Original) | Anti-FAP scFv |
CBL-BiIE009-61 | FAP-CD3 BiIE | OKT3 (Revised) | Anti-FAP scFv |
CBL-BiIE009-62 | Tenascin-CD3 BiIE | OKT3 (Original) | Anti-Tenascin scFv |
CBL-BiIE009-63 | Tenascin-CD3 BiIE | OKT3 (Revised) | Anti-Tenascin scFv |
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.